Neuravi Ltd.

Article preview from Start Up - September, 2010

Neuravi Ltd.'s thrombus capture and removal device for acute stroke patients is designed to disengage offending clots from the wall of brain arteries, and then scaffold the clot inside a microfiber net during removal from the patient. The company thinks its technology represents a major advancement for the treatment of stroke because currently available products do not offer an effective clot disengagement system.

Neuravi Ltd.

Article preview from Start Up - September, 2010

Neuravi Ltd.'s thrombus capture and removal device for treating acute stroke patients is designed to disengage offending clots from the wall of brain arteries, and then scaffold the clot inside a microfiber net during removal from the patient. The company thinks its technology represents a major advancement for the treatment of stroke because currently available products do not offer an effective clot disengagement system. The Neuravi device has a dedicated clot disengagement feature to break bonds and reduce the friction between the clot and vessel wall.

Neuravi is initially targeting the roughly 250,000 stroke patients with large vessel occlusions that are treated each year in the US, representing a market opportunity of about $1 billion.

The major co-founder of the Irish-start-up is Eamon Brady, Neuravi's CEO, who previously worked at Abbott Vascular Inc. from 2004 to 2008, where, as director of new ventures, he "became very aware of the huge need for a solution to treat acute ischemic stroke." "In fact, 95% of people receive no intervention for this extremely debilitating disease," he states. Brady also served as director of R&D and director of intellectual property at MedNova Ltd., a stroke prevention company that developed and commercialized embolic filters and carotid stents, from 1997 to 2004.

In 2008, Brady and co-founder Mahmood Razavi, director of the Center for Clinical Trials and Research at St. Joseph Hospital Heart and Vascular Center in Orange, CA, discussed a handful of projects they might pursue together. "We both agreed that acute stroke is desperately in need of new technology," Razavi recalls.

Developing a new device for acute stroke is challenging because brain arteries are tiny, delicate and tortuous. "We needed a system that provided a complete capture and efficient disengagement of the clot," Razavi says.

Purchase this article online or get it FREE when you subscribe to Start Up

Companies mentioned in this article:

Neuravi Ltd

Elsevier Business Intelligence announces the publication of a new Special Report "Bigger, Tougher,Faster"- Preparing for the New FDA. When the inspector comes calling ... will you be ready?

This 16-page report originally published in "The Silver Sheet". Learn more... 
About Start Up

No publication reviews leading edge companies and technology better than START-UP. Each issue of START-UP profiles the most important new product companies, identifies the hottest technology areas, reviews funds flowing into private companies and investment trends, and reports on university tech transfer licensing. Industries covered: pharmaceuticals, biotechnology, medical equipment & devices, and in vitro diagnostics.

Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985 9512